Therefore, co-administration of certain drugs (e.g., enzyme-inducing antiepileptic drugs) interacting with an elimination pathway (e.g., CYP metabolism) of the drug in question potentially confounds the impact of obesity on clearance. The gene discussed is PPIG; the disease is obesity disorder.